- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00920842
Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant
Metabolic Syndrome Following Transplant for Leukemia
RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood leukemia who have undergone stem cell transplant may help doctors learn more about the disease and the long-term effects of leukemia treatment. It may also help improve the quality of life for future cancer survivors.
PURPOSE: This clinical trial is studying metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone stem cell transplant.
Panoramica dello studio
Stato
Descrizione dettagliata
OBJECTIVES:
- To determine the prevalence of metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone hematopoietic stem cell transplantation (HSCT) and compare the extent to which prevalence is higher in HSCT survivors than in age- and gender-matched population norms derived from the Third National Health and Nutrition Examination Survey (NHANES III).
- To evaluate the relationship between insulin resistance and risk factors associated with metabolic syndrome (e.g., hypertension, obesity, hyperinsulinemia, and dyslipidemia) as measured by euglycemic insulin clamp, fasting serum insulin, glucose, lipids (total cholesterol, triglycerides, LDL-C, and HDL-C), blood pressure and anthropometric measurements, and DEXA scan in these patients and compare to age- and gender-matched population norms.
- To assess the extent to which prevalent obesity and insulin resistance are correlated with other factors that have been identified in the causal pathway associated with the development of metabolic syndrome and that may be altered after HSCT, including growth hormone secretion, adipokines (adiponectin and leptin), and inflammatory mediators (interleukin-6, tumor necrosis factor-α, and C-reactive protein).
- To evaluate the association of metabolic syndrome and early signs of impaired endothelial function and cardiovascular changes.
- To evaluate health behaviors related to prevention of cardiovascular disease, diabetes, and obesity, including a physical activity assessment, a dietary assessment, and a health knowledge assessment that will be used in the analyses of metabolic syndrome, growth hormone deficiency, and indicators of cardiovascular disease.
OUTLINE: Patients are stratified according to post-transplant follow-up period (2-9 years vs 10-15 years vs > 15 years).
Patients and their siblings undergo physical examination, a review of medical and family history, and blood pressure and anthropometric measurements. Patients and their siblings also undergo blood sample collection for laboratory studies (including analysis of C-reactive protein and CBC; lipid profile and triglycerides; leptin and adipokines; free thyroxine, TSH, IGF1, IGF3, and LH; and estradiol [females] or testosterone [males]); urine sample collection for microalbumin determination; and other study procedures (including euglycemic insulin clamp study; body composition and bone density [DEXA] study; bone-age x-ray [for patients < 18 years of age]; and vascular studies). Patients also undergo growth hormone stimulation testing.
Patients and their siblings complete questionnaires about their physical activity, dietary habits, and health knowledge.
PROJECTED ACCRUAL: A total of 193 childhood leukemia survivors and 193 healthy siblings will be accrued for this study.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Clinical Research Center - Seattle Children's Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
DISEASE CHARACTERISTICS:
Meets 1 of the following criteria:
Survivor of childhood leukemia, meeting all of the following criteria:
- 21 years of age and under at diagnosis
- Has undergone hematopoietic stem cell transplantation (HSCT) at Fairview University Medical Center or Fred Hutchinson Cancer Research Center ≥ 2 years ago
- Disease in remission
- Healthy sibling of a childhood leukemia survivor
PATIENT CHARACTERISTICS:
- Not pregnant
- Negative pregnancy test
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Comparison of the prevalence of metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone hematopoietic stem cell transplantation (HSCT) with age- and gender-matched controls
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Comparison of insulin resistance in patients with age- and gender-matched controls
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Correlation between insulin sensitivity and risk factors associated with metabolic syndrome
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Influence of time since transplant on insulin resistance
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Peak growth hormone secretion in patients with insulin resistance and in those without
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Growth hormone deficiency in patients with metabolic syndrome and in those without
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Association of interleukin-6, tumor necrosis factor-α, C-reactive protein, and leptin with insulin resistance and central obesity
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Correlation of adiponectin with insulin resistance and central obesity
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Differences in markers for endothelium dysfunction and early indicators of cardiovascular disease
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Difference in important health behaviors related to obesity and cardiovascular disease between patients with metabolic syndrome and those without
Lasso di tempo: ≥2 years post-HSCT
|
≥2 years post-HSCT
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: K S Baker, MD, MS, Fred Hutchinson Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- leucemia linfocitica cronica stadio I
- sopravvissuto al cancro
- leucemia linfoblastica acuta infantile in remissione
- leucemia mieloide acuta infantile in remissione
- leucemia mielomonocitica giovanile
- leucemia mieloide cronica infantile
- sindrome metabolica
- effetti a lungo termine secondari alla terapia del cancro nei bambini
- leucemia linfocitica cronica in stadio II
- leucemia linfatica cronica stadio III
- leucemia linfocitica cronica in stadio IV
- complicanze cardiovascolari
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- IR 7141
- P30CA077598 (Sovvenzione/contratto NIH degli Stati Uniti)
- UMN-2003NT063
- CDR0000642276 (Identificatore di registro: NCI)
- IR-6980 (Altro identificatore: Former FHCRC IRB ID)
- FHCRC-2357.00 (Altro identificatore: Former FHCRC ID)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .